Topical ReviewA Review of Childhood and Adolescent Craniopharyngiomas With Particular Attention to Hypothalamic Obesity
Introduction
Craniopharyngiomas are benign cystic epithelial tumors of the sellar or suprasellar region and are the most common nonglial pediatric brain tumor.1 These tumors account for 6-15% of intracranial tumors in childhood and adolescence and account for 80% of neoplasms disrupting the hypothalamic-hypophyseal pathway.2, 3 Patients present with various symptoms and signs that are related to the size and location of the tumor. Because craniopharyngiomas originate adjacent to delicate structures, significant complications from the tumor or treatment may occur, including visual loss, neurological and behavioral deficits, endocrinopathies, cerebral vascular disease, hypothalamic dysfunction, or a syndrome of hypothalamic obesity. The Centers for Disease Control and Prevention defines obesity as having a body mass index (BMI) greater than the 95th percentile for age, overweight as being 85th-95th percentile for age, and underweight as <5th percentile for age. Hypothalamic obesity occurs in 60-80% of cases.4, 5, 6 The National Cancer Database showed survival rates for children <20 years of age were 86% at 2 years postdiagnosis and 80% at 5 years postdiagnosis.7 We reviewed 24 patients with craniopharyngiomas with regard to recurrence, morbidity, mortality, and the impact of obesity on outcome.
Section snippets
Patients and Methods
After obtaining institutional review board approval, we retrospectively reviewed the charts of 24 children diagnosed with craniopharyngiomas who were treated at our institution between 1992 and 2010. Their sex, ethnicity, age at diagnosis, weight and height, course of treatment, follow-up, and morbidity/mortality were recorded. BMI was calculated and percentiles were obtained using the Centers for Disease Control and Prevention sex-specific growth charts from May 2000. Magnetic resonance scans
Demographics
In our cohort, 12 of the 24 patients were male (50%). Our ethnic demographics were 13 white, 7 Latino, and 4 Native American. The mean age at diagnosis was 10.6 years (range 2-16 years). The mean follow up was 5.03 years (range 1 month to 14 years). Specific demographics for all 24 patients are shown in Table 1.
Neuroradiology
All 24 (100%) patients had a cystic component to their tumor. Seventeen (70%) of the patients had an associated solid component, and 4 (16%) had additional calcifications. Eleven
Discussion
Craniopharyngiomas are tumors arising from remnants of squamous epithelium of the craniopharyngial duct. The term craniopharyngioma was first introduced by Harvey Cushing in 1932.8 These tumors are considered benign neoplasms with biologic behavior consistent with Grade I tumors by World Health Organization classification. Although long-term survival for patients with pediatric craniopharyngiomas has been as high as 80-90%, tumor and treatment related morbidity is significant.9 Because of their
References (51)
- et al.
Craniopharyngioma in childhood
Adv Pediatr
(2006) - et al.
Long term results of multimodality treatment of craniopharyngioma in children
J Clin Neurosci
(1999) - et al.
On the benefits and risks of proton therapy in pediatric craniopharyngioma
Int J Radiat Oncol Biol Phys
(2012) - et al.
Phosphorus-32 intracavitary irradiation of cystic craniopharyngiomas: current technique and long-term results
Int J Radiat Oncol Biol Phys
(1995) - et al.
Phosphorus-32 therapy for cystic craniopharyngiomas
Radiother Oncol
(2011) The neuroendocrinology of obesity
Endocrinol Metab Clin North Am
(2001)- et al.
Craniopharyngioma Clinical Status Scale: a standardized metric of preoperative function and posttreatment outcome
Neurosurg Focus
(2010) - et al.
Craniopharyngiomas
Endocr Rev
(2006) - et al.
The use of dextroamphetamine to treat obesity and hyperphagia in children treated for craniopharyngioma
Arch Pediatr Adolesc Med
(2002) - et al.
Outcome of craniopharyngioma in children: long-term complications and quality of life
Dev Med Child Neurol
(2004)
Hypothalamic obesity; the sixth cranial endocrinopathy
Endocrinologist
The descriptive epidemiology of craniopharyngioma
J Neurosurg
The Craniopharyngioma. Intracranial Tumours
Health status in long-term survivors of pediatric craniopharyngiomas
J Neurosci Nurs
Craniopharyngiomas: a clinicopathological analysis of factors predictive of recurrence and functional outcome
Neurosurgery
Craniopharyngioma in adults and children: a study of 122 surgical cases
J Neurosurg
Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up
Clin Endocrinol (Oxf)
Long-term clinical outcomes following treatment of childhood craniopharyngioma
Pediatr Blood Cancer
Aggressive surgical management of craniopharyngiomas in children
J Neurosurg
Surgical treatment of craniopharyngiomas: experience with 168 patients
J Neurosurg
Radical resections of childhood craniopharyngiomas
Pediatr Neurosurg
Craniopharyngioma
Craniopharyngioma: results of survey of the American Society of Pediatric Neurosurgery
Pediatr Neurosurg
Total removal of craniopharyngiomas. Approaches and long-term results in 144 patients
J Neurosurg
Craniopharyngioma: a comparison of tumor control with various treatment strategies
Neurosurg Focus
Cited by (35)
A Comparison of Long-Term Treatment Outcomes Between Giant and Nongiant Craniopharyngiomas
2022, World NeurosurgeryCitation Excerpt :However, radical surgery is often associated with significant neurological- and endocrinological-hypothalamic dysfunction due to the critical location of these tumors, and cannot completely eliminate the risk of recurrence.5-7 A conservative policy of maximal safe resection supplemented with adjuvant radiation therapy (RT) has been championed as a less morbid, yet effective alternative approach to these tumors.5,8-13 Nevertheless, the deleterious effects of cranial irradiation on cognition, vision, and endocrine function remain incompletely defined, particularly on long-term follow-up.
Adipsic diabetes insipidus
2021, Handbook of Clinical NeurologyCitation Excerpt :Tumors, surgical procedures, and radiation therapy may disrupt these feeding circuits by damaging the medial hypothalamic nuclei (Rosenfeld et al., 2014; Abuzzahab et al., 2019). These processes may increase hunger through two proposed mechanisms: either by unopposed activation of orexigens in the lateral hypothalamus or by inadequate responses to leptin and proopiomelanocortin in the arcuate nucleus, which is located in the medial hypothalamus (Rosenfeld et al., 2014). Nuclei involved in HO and disruption of energy metabolism include the arcuate (or infundibular) nucleus, PVN, ventromedial nucleus, dorsomedial nucleus, and dorsal hypothalamic area (Abuzzahab et al., 2019).
Liraglutide for the Treatment of Hypothalamic Obesity
2018, AACE Clinical Case ReportsCitation Excerpt :HO has specifically been reported in 53% of patients after treatment for craniopharyngioma (5). Individuals with HO have a reduction in functional capacity, decrease in quality of life, and increase in morbidity and mortality from cardiovascular disease, diabetes mellitus, and liver disease (5). Although there have not been large, robust medical trials for HO management, there are small case reports describing several treatment modalities.
Clinical Characteristics of Childhood-Onset Craniopharyngioma
2024, Alternative Therapies in Health and MedicineIntegrating Systemic Therapies into the Multimodality Therapy of Patients with Craniopharyngioma
2024, Current Treatment Options in OncologyGlobal pediatric craniopharyngioma management modalities and outcomes
2024, Child's Nervous System